Ian Lichfield, CEO of WHP Engineering figuratively sat down with BioProcess Insider to discuss the key things to consider when planning a facility and how the business will adapt to suspected future changes. WHP Engineering is located in Newcastle, UK and describes itself on LinkedIn as a “multi-disciplined, engineering company dedicated to providing both standalone and turnkey solutions for highly-regulated, controlled environments and complex manufacturing processes across Europe.” The firm works with a wide range of customers in the life…

Moderna will build an mRNA vaccine manufacturing plant in Victoria, Australia, which could produce up to 100 million doses each year, says firm. Moderna, which sprang to success on the back of its COVID-19 vaccine, laid out plans to construct a $500 million African messenger RNA (mRNA) facility in October. Now, the firm has announced an agreement with the Australian Government to build an mRNA vaccine plant in Victoria, including access to Moderna’s mRNA development technology. While the deal has…

Fujifilm Diosynth Biotechnologies (FDB) will increase its advanced therapy and vaccine production capacity by constructing a $300 million facility in Texas. Contract development manufacturing organization (CDMO) FDB will expand its single-use manufacturing campus in College Station, Texas by adding a production facility that will double the firm’s advanced therapy and vaccine manufacturing capacity in the US. “As the need for advanced therapies development and manufacturing capacity grows, we will continue to invest in the right technology and talent to support…

Novo Nordisk will invest $2.5 billion to construct three manufacturing facilities and expand its Kalundborg, Denmark site. According to Danish drugmaker Novo Nordisk, the expansion will support production of Novo Nordisk’s current and future injectable and oral products, including insulin. A spokesperson for Novo Nordisk told BioProcess Insider its Kalundborg site has been selected because the firm has “more than 50 years’ experience out of Kalundborg in Denmark; about 50 % of the total insulin production comes from Kalundborg; we…

Evolve Biologics has chosen Sachse, Texas as the site of its first plasma-derived therapeutics facility. Canadian-headquartered firm Evolve says the site selection and purchase of land establishes the company’s drive towards the commercialization of plasma-derived therapeutics. “Northern Texas has a growing corporate/pharmaceutical presence which enables collaboration and attracts a highly skilled workforce. The Dalls Fort Worth area also has a very strong educational base, including many high caliber and local universities, which is great for recruiting,” said David Holliday, Chief…